Stapokibart for primary cutaneous amyloidosis
Treatments studied
Part of Skin clinical trials.
This study tests an investigational injection (Stapokibart) for people with moderate to severe primary cutaneous amyloidosis, a condition that causes itchy, thickened skin. It aims to see if the drug can safely reduce symptoms in people who haven't gotten enough relief from standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your skin condition, called primary cutaneous amyloidosis, must be confirmed by a biopsy and be moderately to severely active.
- You have tried strong prescription creams or steroid pills, but they didn't control your symptoms.
- You are willing to use a moisturizer every day for the study.
- You cannot have used certain immune-suppressing medications or biologics in the past few weeks to months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at people with primary cutaneous amyloidosis who have been treated with Avastin Capsules or Tofacitinib Citrate. It aims to track how well these medications work and if they are safe over time.
This trial tests a new injectable drug, Stapokibart, for people with moderate to severe bullous pemphigoid, a blistering skin condition. The goal is to see if the drug can help reduce blistering and itching.
This study tests a new injection medicine called Stapokibart for treating atopic dermatitis (a chronic skin condition causing itching and inflammation). Your doctor has already decided this medicine might help you before you joined the study.
This trial tests an experimental medication (Stapokibart) for children ages 2 to 11 with moderate-to-severe eczema that hasn't improved with topical creams. The goal is to see if the new treatment can help control their symptoms.
This trial tests a medicine called Stapokibatrt in children with atopic dermatitis (eczema). It is for kids who already completed the main study and may help manage their skin condition.
This trial tests an investigational drug called Stapokibart (CM310) for people with non-allergic rhinitis with eosinophilia syndrome (NARES). It aims to see if the drug can better control persistent nasal symptoms like congestion, runny nose, and sneezing when standard treatments aren't enough.
Hear when a new Primary Cutaneous Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.